GM enters the final week of August with a striking contradiction at its heart: options traders are the most bullish they have been all year, yet the executives running the company spent the past month selling stock at the fastest pace visible in recent data.
The options signal is the sharpest data point this week. The put/call ratio has dropped to 0.63, nearly three standard deviations below its 20-day average of 0.70 — the most call-heavy reading of the past 52 weeks, which bottoms at 0.58. That is an unusually pronounced tilt toward upside positioning, and it has emerged just as the stock has given back about 1.3% in Tuesday's session after climbing 2.5% on the week to $85.81. Short interest, at 2.2% of the free float, is a non-story from a crowding perspective — it ticked up 7% in a single day on August 25 but remains well below the roughly 3% level that prevailed through late July. Borrow conditions are extremely loose: availability is essentially unlimited, and cost to borrow has eased back to around 0.34% after briefly touching 0.67% on August 7. Nothing in the lending market suggests any squeeze dynamic.
The insider picture cuts the other way. Four senior executives — CEO Mary Barra, President Mark Reuss, EVP Sterling Anderson, and EVP Grant Dixton — all sold shares in the $88–$90 range between July 28 and August 3, with Barra alone accounting for more than $19 million across three separate transactions. The 90-day net across all insiders is positive in share terms largely because of equity awards granted to Anderson and Dixton on July 29–30, but those awards are non-cash. Strip them out, and the cash-transaction picture is one-directional: senior management has been a seller into this rally.
The Street, however, is broadly constructive. Following GM's Q2 print on July 21 — which sent the stock up 8.4% in a day and 19% over the following five sessions — virtually every major firm lifted its target. JP Morgan raised its target to $120, Goldman Sachs moved to $103, and Barclays went to $110, all while holding positive ratings. Jefferies made the most decisive move, upgrading outright from Hold to Buy with a $99 target. The lone dissenter, Wells Fargo, nudged its Underweight target to $61 — a figure that looks increasingly disconnected from where the stock is trading. The mean analyst target of around $101 implies roughly 18% upside from current levels, and the forward earnings multiple of just over 6x keeps the value argument alive. The analyst recommendation differential factor ranks in the 98th percentile of the ORTEX universe — as close to a consensus overweight as a stock gets.
The bull case rests on diversification away from the traditional auto cycle: OnStar, GM Defense, and GM Insurance are each growing faster than the core vehicle business, and the 12-month forward EPS growth factor scores in the 92nd percentile. Bears point to the cyclicality that never fully goes away, as well as a stock that has already run hard — up about 8% year-to-date and trading near the price at which its own CEO chose to sell. Peers had a quieter week: F was essentially flat, while European names STLAM and VOW3 each added around 2% and 0.4% respectively, suggesting GM's weekly gain was broadly in line with the sector rather than a standout move.
The next scheduled catalyst is Q3 earnings on October 20, and given that the last two quarterly prints produced an 8% and a -1% day-one reaction respectively, the setup heading into that date — whether options remain this call-skewed and whether insiders have resumed selling — will be the variables worth tracking.
See the live data behind this article on ORTEX.
Open GM on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
